Issue Archive

In this Review Series, introduced by Associate Editor Thomas L. Ortel, experts contribute 6 seminal reviews that focus on the treatment of venous thromboembolism (VTE) in adults and children, the management of VTE developing in unusual locations and in the setting of thrombophilia, and new targets and antithrombotic therapies in development.

In this Review Series, introduced by Associate Editor Thomas L. Ortel, experts contribute 6 seminal reviews that focus on the treatment of venous thromboembolism (VTE) in adults and children, the management of VTE developing in unusual locations and in the setting of thrombophilia, and new targets and antithrombotic therapies in development.

In this Review Series, introduced by Associate Editor Thomas L. Ortel, experts contribute 6 seminal reviews that focus on the treatment of venous thromboembolism (VTE) in adults and children, the management of VTE developing in unusual locations and in the setting of thrombophilia, and new targets and antithrombotic therapies in development.

In this Review Series, introduced by Associate Editor Thomas L. Ortel, experts contribute 6 seminal reviews that focus on the treatment of venous thromboembolism (VTE) in adults and children, the management of VTE developing in unusual locations and in the setting of thrombophilia, and new targets and antithrombotic therapies in development.

In this Review Series, introduced by Associate Editor Thomas L. Ortel, experts contribute 6 seminal reviews that focus on the treatment of venous thromboembolism (VTE) in adults and children, the management of VTE developing in unusual locations and in the setting of thrombophilia, and new targets and antithrombotic therapies in development.

In this Review Series, introduced by Associate Editor Thomas L. Ortel, experts contribute 6 seminal reviews that focus on the treatment of venous thromboembolism (VTE) in adults and children, the management of VTE developing in unusual locations and in the setting of thrombophilia, and new targets and antithrombotic therapies in development.

In this Review Series, introduced by Associate Editor Thomas L. Ortel, experts contribute 6 seminal reviews that focus on the treatment of venous thromboembolism (VTE) in adults and children, the management of VTE developing in unusual locations and in the setting of thrombophilia, and new targets and antithrombotic therapies in development.

In the largest series to date, Laurent and colleagues reveal that the genomic landscape of breast implant–associated anaplastic large cell lymphomas (ALCLs) is characterized not only by previously recognized JAK/STAT-activating mutations, but also by loss-of-function alterations of epigenetic modifiers. This provides new insights into the pathogenesis of these neoplasms.

In a retrospective analysis of RATIFY trial data, Döhner and colleagues investigated the prognostic and predictive impact of the NPM1/FLT3-ITD genotypes categorized according to the 2017 European LeukemiaNet (ELN) risk groups. Their work informs clinical practice by indicating a beneficial effect of adding midostaurin to standard chemotherapy in all ELN risk groups.

Patients with Philadelphia-negative myeloproliferative neoplasms are prone to the development of second cancers. In an international nested case-control study, De Stefano and colleagues identified an association between a new event of arterial thrombosis and the subsequent diagnosis of a second cancer.

Pan and colleagues report one of the first prospective evaluations of planned sequential chimeric antigen receptor (CAR) T-cell therapy targeting CD19 and then CD22 in a phase 1 trial, indicating acceptable toxicity and encouraging durable efficacy in pediatric patients with relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL).